Commentary
Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer
-
Correspondence: Carlos L Arteaga carlos.arteaga@vanderbilt.edu
Breast Cancer Res 2003, 5:96-100 doi:10.1186/bcr574
No comments have yet been made on this article.